Home › Funds › a16z Capital Management, L.L.C. › KLRA
a16z Capital Management, L.L.C. position in KLRA
KAILERA THERAPEUTICS INC · Health Care
a16z Capital Management, L.L.C. reported holding 140,000 shares of KLRA (KAILERA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.6M, representing 0.01% of its reported portfolio and ranking #18 among its reported holdings. a16z Capital Management, L.L.C. has disclosed KLRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How a16z Capital Management, L.L.C.'s KLRA position evolved
a16z Capital Management, L.L.C. first disclosed a stake in KLRA in Q2 2026 at 140,000 shares (US$3.1M). Across 2 filings, a16z Capital Management, L.L.C. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 140,000 shares valued at US$1.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 140.00K | $3.08M | New |
| Q3 2026 | 140.00K | $1.60M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KLRA and 13F data
KLRA (KAILERA THERAPEUTICS INC) is a Health Care company. 137 other funds we track also report a position in KLRA — the largest reported positions include BAIN CAPITAL INVESTORS LLC (US$299.8M), Bain Capital Life Sciences Investors, LLC (US$257.9M), RTW INVESTMENTS, LP (US$123.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KLRA
- BAIN CAPITAL INVESTORS LLC 26.26M sh · $299.84M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 22.58M sh · $257.90M · Q3 2026
- RTW INVESTMENTS, LP 10.78M sh · $123.07M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 5.17M sh · $59.06M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 2.46M sh · $28.04M · Q3 2026
- Siren, L.L.C. 2.21M sh · $25.29M · Q3 2026
- Farallon Capital Management 1.10M sh · $24.23M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.20M sh · $13.70M · Q3 2026
- Trails Edge Capital Partners, LP 942.95K sh · $10.77M · Q3 2026
- Vestal Point Capital, LP 625.00K sh · $7.14M · Q3 2026
- Catalio Capital Management, LP 468.75K sh · $5.35M · Q3 2026
- Cormorant Asset Management, LP 400.00K sh · $4.57M · Q3 2026
More on a16z Capital Management, L.L.C.
FAQ
How long has a16z Capital Management, L.L.C. held KLRA?
a16z Capital Management, L.L.C. has disclosed KLRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is a16z Capital Management, L.L.C.'s current position in KLRA?
As of Q3 2026, a16z Capital Management, L.L.C. holds 140.00K shares of KLRA (KAILERA THERAPEUTICS INC), valued at $1.60M, representing 0.01% of its reported portfolio and ranking #18.
Has a16z Capital Management, L.L.C. been buying or selling KLRA?
In the latest 13F filing (Q3 2026), a16z Capital Management, L.L.C. held unchanged its position in KLRA.
Which other funds hold KLRA?
Other major institutional holders of KLRA include BAIN CAPITAL INVESTORS LLC, Bain Capital Life Sciences Investors, LLC, RTW INVESTMENTS, LP, among 137 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.